A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir-Reference-Cited by-同舟云学术

A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir

Published:2022-10-27 Issue:11 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Ramirez-Sanchez Claudia¹^ORCID,Kozuch Jade²,Shah Mita M³,Berumen Jennifer⁴,Mekeel Kristin⁴,Schnickel Gabriel⁴,Taremi Mahnaz¹,Golts Eugene⁵,Afshar Kamyar⁶,Adler Eric⁷^ORCID,Pretorius Victor⁵,Aslam Saima¹

Affiliation:

1. Division of Infectious Diseases and Global Public Health, University of California San Diego , La Jolla, California , USA

2. Department of Pharmacy, University of California San Diego , La Jolla, California , USA

3. Division of Nephrology, University of California San Diego , La Jolla, California , USA

4. Division of Transplant and Hepatobiliary Surgery, University of California San Diego , La Jolla, California , USA

5. Division of Cardiothoracic Surgery, University of California San Diego , La Jolla, California , USA

6. Division of Pulmonary and Critical Care, University of California San Diego , La Jolla, California , USA

7. Division of Cardiology, University of California San Diego , La Jolla, California , USA

Abstract

Abstract A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac550/46650331/ofac550.pdf

Reference19 articles.

1. Outcomes of heart transplantation from hepatitis C virus-positive donors;Aslam;J Heart Lung Transplant,2019

2. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study;Bethea;Lancet Gastroenterol Hepatol,2019

3. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors;Kwong;Am J Transplant,2018

4. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial;Durand;Ann Intern Med,2018

5. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings;Assoumou;Clin Infect Dis,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organ Donors with Human Immunodeficiency Virus and Hepatitis C Virus;Infectious Disease Clinics of North America;2023-09

2. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection;Clinical Infectious Diseases;2023-05-25